Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis

被引：18

作者：

Ben Yahia S. ^{[1
]}

Herbort C.P. ^{[2
,3
]}

Jenzeri S. ^{[1
]}

Hmidi K. ^{[1
]}

Attia S. ^{[1
]}

Messaoud R. ^{[1
]}

Khairallah M. ^{[1
]}

机构：

[1] Department of Ophthalmology, Fattouma Bourguiba University Hospital

[2] Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialized Care, Lausanne

[3] University of Lausanne, Lausanne

来源：

International Ophthalmology | 2008年 / 28卷 / 4期

关键词：

Bevacizumab; Choroidal neovascularization; Ocular toxoplasmosis; Vascular endothelial growth factor;

D O I：

10.1007/s10792-008-9218-2

中图分类号：

学科分类号：

摘要：

Background: Treatment modalities for choroidal neovascularization due to ocular toxoplasmosis include laser photocoagulation, surgery, corticosteroids, and verteporfin therapy. Intravitreal injection of bevacizumab in the treatment of choroidal neovascularization due to other conditions appears to be an effective and safe therapeutic option. Case reports: We report two young patients with choroidal neovascularization secondary to ocular toxoplasmosis who received a single intravitreal injection of bevacizumab as primary or rescue therapy. After a follow-up of 12 and 10 months, respectively, visual acuity improved, and features of active neovascularization resolved with no recurrence. No adverse events were recorded. Conclusion: Intravitreal injection of bevacizumab appears to be an effective and safe treatment modality in patients with choroidal neovascularization secondary to ocular toxoplasmosis. Further evaluation with a longer follow-up period is needed to confirm these findings. © Springer Science+Business Media B.V. 2008.

引用

页码：311 / 316

页数：5

共 10 条

[1]

Adan A., Mateo C., Wolley-Dod C., Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis, Am J Ophthalmol, 135, pp. 386-387, (2003)

[2]

Wirthlin R., Song A., Song J., Rosenfeld P.J., Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis, Arch Ophthalmol, 124, pp. 741-743, (2006)

[3]

Perentes Y., Van Tran T., Sickenberg M., Herbort C.P., Subretinal neovascular membranes complicating uveitis: Frequency, treatments and visual outcome, Ocul Immunol Inflamm, 13, pp. 219-224, (2005)

[4]

Avery R.L., Pieramici D.J., Rabena M.D., Et al., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology, 113, pp. 363-372, (2006)

[5]

Laud K., Spaide R.F., Freund K.B., Et al., Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab, Retina, 26, pp. 960-963, (2006)

[6]

Teixeira A., Moraes N., Farah M.E., Bonomo P.P., Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks, Acta Ophthalmol Scand, 84, pp. 835-836, (2006)

[7]

Kwak N., Okamoto N., Wood J.M., Campochiaro P.A., VEGF is major stimulator in model of choroidal neovascularization, Invest Ophthalmol Vis Sci, 41, pp. 3158-3164, (2000)

[8]

Perentes Y., Chan C.C., Bovey E., Uffer S., Herbort C.P., Massive vascular endothelial growth factor (VEGF) expression in Eales' disease, Klin Monatsbl Augenheilk, 219, pp. 11-14, (2002)

[9]

Shahar J., Avery R.L., Heilweil G., Et al., Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin), Retina, 26, pp. 262-269, (2006)

[10]

Adan A., Mateo C., Navarro R., Et al., Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization, Retina, 27, pp. 1180-1186, (2007)

← 1 →